Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by Simplify Asset Management Inc.

Simplify Asset Management Inc. lifted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 251.1% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,981 shares of the biopharmaceutical company’s stock after buying an additional 9,284 shares during the quarter. Regeneron Pharmaceuticals makes up about 0.1% of Simplify Asset Management Inc.’s investment portfolio, making the stock its 21st largest holding. Simplify Asset Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $7,299,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Marino Stram & Associates LLC grew its holdings in Regeneron Pharmaceuticals by 5.3% during the 2nd quarter. Marino Stram & Associates LLC now owns 396 shares of the biopharmaceutical company’s stock worth $208,000 after acquiring an additional 20 shares in the last quarter. CX Institutional lifted its position in shares of Regeneron Pharmaceuticals by 7.9% during the second quarter. CX Institutional now owns 302 shares of the biopharmaceutical company’s stock worth $159,000 after purchasing an additional 22 shares during the last quarter. Independence Bank of Kentucky grew its stake in Regeneron Pharmaceuticals by 7.7% in the third quarter. Independence Bank of Kentucky now owns 308 shares of the biopharmaceutical company’s stock worth $173,000 after purchasing an additional 22 shares in the last quarter. Redwood Wealth Management Group LLC increased its holdings in Regeneron Pharmaceuticals by 4.8% in the second quarter. Redwood Wealth Management Group LLC now owns 506 shares of the biopharmaceutical company’s stock valued at $266,000 after buying an additional 23 shares during the last quarter. Finally, Princeton Capital Management LLC lifted its holdings in Regeneron Pharmaceuticals by 1.9% during the 2nd quarter. Princeton Capital Management LLC now owns 1,240 shares of the biopharmaceutical company’s stock worth $651,000 after buying an additional 23 shares during the last quarter. Institutional investors own 83.31% of the company’s stock.

Wall Street Analyst Weigh In

REGN has been the subject of a number of research analyst reports. Truist Financial started coverage on Regeneron Pharmaceuticals in a report on Monday, November 24th. They issued a “buy” rating and a $798.00 price target for the company. BMO Capital Markets lifted their price objective on shares of Regeneron Pharmaceuticals from $725.00 to $850.00 and gave the stock an “outperform” rating in a report on Thursday, December 4th. Cantor Fitzgerald boosted their target price on shares of Regeneron Pharmaceuticals from $678.00 to $740.00 and gave the company an “overweight” rating in a research note on Wednesday, October 29th. Royal Bank Of Canada raised their price target on shares of Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the stock a “sector perform” rating in a research report on Wednesday, October 29th. Finally, Morgan Stanley boosted their price objective on shares of Regeneron Pharmaceuticals from $767.00 to $768.00 and gave the company an “equal weight” rating in a research report on Friday, December 12th. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $779.45.

Regeneron Pharmaceuticals Stock Down 0.6%

Regeneron Pharmaceuticals stock opened at $780.50 on Tuesday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.33 and a current ratio of 4.06. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $792.77. The company has a 50-day simple moving average of $707.58 and a 200-day simple moving average of $612.72. The firm has a market capitalization of $82.03 billion, a P/E ratio of 18.69, a P/E/G ratio of 2.26 and a beta of 0.37.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $9.73 by $2.10. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The firm had revenue of $3.75 billion during the quarter, compared to analyst estimates of $3.57 billion. During the same period in the previous year, the business posted $12.46 EPS. Regeneron Pharmaceuticals’s revenue was up .9% on a year-over-year basis. As a group, equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, December 5th. Investors of record on Thursday, November 20th were issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date of this dividend was Thursday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio is 8.43%.

Insider Buying and Selling

In other news, VP Jason Pitofsky sold 431 shares of the stock in a transaction on Friday, November 7th. The stock was sold at an average price of $651.43, for a total value of $280,766.33. Following the completion of the transaction, the vice president owned 4,233 shares of the company’s stock, valued at approximately $2,757,503.19. This represents a 9.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Christine A. Poon sold 6,500 shares of the firm’s stock in a transaction on Wednesday, October 29th. The shares were sold at an average price of $654.27, for a total value of $4,252,755.00. Following the transaction, the director directly owned 2,352 shares in the company, valued at $1,538,843.04. This trade represents a 73.43% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 7.02% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.